Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Quince Therapeutics, Inc. QNCX
$1.54
-$0.1 (-6.67%)
На 17:51, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
60582423.00000000
-
week52high
3.85
-
week52low
0.54
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.37536700
-
EPS
-1.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 04:00
Описание компании
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Underperform | Underperform | 11 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 09 мар 2022 г. |
| Canaccord Genuity | Hold | Buy | 28 янв 2022 г. |
| JMP Securities | Market Perform | Market Outperform | 27 янв 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Thye Dirk | A | 600000 | 600000 | 01 февр 2023 г. |
| Smith Karen L. | A | 225000 | 225000 | 01 февр 2023 г. |
| Hannah Brendan | A | 225000 | 225000 | 01 февр 2023 г. |
| Monohon Ted | A | 110000 | 110000 | 01 февр 2023 г. |
| Monohon Ted | D | 29311 | 1640 | 05 дек 2022 г. |
| Monohon Ted | D | 30951 | 1520 | 06 сент 2022 г. |
| Monohon Ted | A | 250000 | 250000 | 29 июн 2022 г. |
| Bray June | A | 54000 | 54000 | 09 июн 2022 г. |
| McLoughlin Margaret | A | 27000 | 27000 | 08 июн 2022 г. |
| Lamond David | A | 27000 | 27000 | 08 июн 2022 г. |
Новостная лента
How to Identify Potentially Profitable Penny Stocks to Buy
PennyStocks
29 янв 2023 г. в 06:00
Use these tips for finding penny stocks to buy The post How to Identify Potentially Profitable Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Quince Therapeutics (NASDAQ:QNCX) Stock Up 53% Today?
InvestorPlace
27 янв 2023 г. в 10:20
Quince Therapeutics (NASDAQ: QNCX ) stock is rocketing higher on Friday after completing an asset sale to Lighthouse Pharmaceuticals. This sale covers the company's legacy small molecule protease inhibitor portfolio.
Quince Therapeutics to Present at Upcoming Scientific Meetings
Business Wire
25 авг 2022 г. в 16:05
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a number of scientific meetings taking place in September 2022, including the 14th International Conference on Osteogenesis Imperfecta (OI 2022), The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), and the Military Health Syst
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
InvestorPlace
15 мар 2022 г. в 12:56
Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today appeared first on InvestorPlace.
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
Benzinga
08 мар 2022 г. в 11:27
Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.